Validation of the 2018 FIGO Staging System of Cervical Cancer for Stage III Patients with a Cohort from China

Abstract

Purpose To validate the 2018 revised FIGO cervical cancer staging system for stage III patients with a cohort from China. Patients and Methods Patients with stage III cervical cancer (FIGO 2018) treated with definitive radiotherapy at our institute were reviewed. Each patient was evaluated with both the 2014 and 2018 staging systems. Disease-free survival (DFS) was calculated with the Kaplan-Meier method. Receiver operative characteristic (ROC) curves for the predictive accuracy of DFS in patients with cervical cancer according to different FIGO staging systems were created. Results Between January 2008 and December 2014, a total of 586 patients with FIGO stage IIIC cervical cancer (2018) were treated with definitive radiotherapy at our institute. The 3-year DFS for patients according to FIGO stage (2014) were as follows: IB2 73.2%, IIA 63.7%, IIB 66.7%, IIIA 64.7%, and IIIB 59.6% (P=0.580). The 3-year DFS according to FIGO stage (2018) were IIIA 79.9%, IIIB 70.4%, IIIC1 66.3% and IIIC2 29.8% (P<0.001). The AUC values for DFS were 0.552 (95% CI: 0.503-0.600, P=0.037) and 0.623 (95% CI: 0.575-0.671, P<0.001) for the 2014 and 2018 FIGO staging systems, respectively. Conclusion The 2018 FIGO staging system of cervical cancer showed more distinction within stages and better predictive accuracy for DFS than the preceding staging system in patients with stage III disease from China.